-+ 0.00%
-+ 0.00%
-+ 0.00%

Gacos-B (01167) announced interim results. Shareholders' revenue of 601 million yuan turned a year-on-year loss into a profit

Zhitongcaijing·08/25/2026 01:17:18
Listen to the news

According to the Zhitong Finance App, Gacos-B (01167) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 731 million yuan, an increase of 1500.5% over the previous year; revenue attributable to company owners was 601 million yuan, and a loss of 58.994 million yuan for the same period last year; basic profit per share was 0.78 yuan.

According to the announcement, revenue growth was mainly due to strategic cooperation with AstraZeneca AB on global R&D, production and commercialization of JAB-23E73; and external licensing and service agreements with Alice for R&D, production and commercialization of Erica® and sitneprotafib.